Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics, Inc. (ARQT) – Form 144 filing: Insider Masaru Matsuda filed notice to dispose of up to 6,330 common shares through Merrill (Columbus, OH) on or after 08/04/2025. At the most recent market price, the proposed sale is valued at $90,687. The shares originate from a restricted-stock vesting on 08/01/2025. Arcutis has 11.92 million shares outstanding, so the sale equals roughly 0.05 % of shares outstanding.
During the past three months Matsuda already sold 6,830 shares for gross proceeds of $101,261 (5/02 & 5/28 2025). Form 144 is a notice only; execution is not assured. By signing, the filer affirms no undisclosed material adverse information exists. No other operational or financial metrics were disclosed.
Arcutis Biotherapeutics, Inc. (ARQT) filed a Form 144 indicating a planned disposition of 89 common shares (≈ $1,255 market value) through Merrill Lynch on or after 4 Aug 2025. The shares represent <0.0001% of the company’s 119.2 million shares outstanding and were acquired via a restricted-stock vest on 1 Aug 2024.
The same insider, Latha Vairavan, previously sold an identical block of 89 shares for $1,329 on 5 May 2025. No other sales or material considerations are disclosed. Form 144 requires the filer to state that they possess no undisclosed adverse information and to acknowledge potential penalties for misstatements.
Investment-relevance: The proposed sale is de minimis and does not alter ownership structure, liquidity, or strategic outlook. It is therefore unlikely to affect ARQT’s valuation or trading dynamics.